

BRUCE KAPLAN, M.D.

EMPLOYMENT:

2/1/21- Present Medical and Scientific Director, Colorado Center for Transplantation Care, Research and Education
University of Colorado School of Medicine
4/2017 – 2021 Vice President Transplant Services Baylor Scott & White Health
Raleigh R White Professor
9/2015 – 2017 Professor of Medicine, Mayo Clinic
Professor in the School for the Science of Healthcare Delivery, Arizona State University
11/2016 –2017 Director of Transplant Research, Mayo Clinic Arizona

EDUCATION:

7/1990 – 6/1991 Research Fellow in Clinical Pharmacology, Internal Medicine, Northwestern University
Medical School, Chicago, Illinois (NIH fellowship with Dr. Arthur Atkinson)
7/1989 – 6/1990 Clinical Fellow in Nephrology, State University of New York at Stony Brook, New York
7/1987 – 6/1989 House Officer in Internal Medicine, Beth Israel Medical Center
8/1986 – 6/1987 Resident in Physical Medicine and Rehabilitation
Mount Sinai School of Medicine, City University of New York
Mount Sinai School of Medicine, City University of New York
7/1985 – 6/1986 Internship, Overlook Hospital, Summit, New Jersey
8/1981 – 5/1985 M.D., Columbia University College of Physicians and Surgeons, New York, New York
8/1977 – 5/1981 B.S, Biology, Adelphi University, Garden City, New York

PAST EMPLOYEMENT (Academic and Administrative Positions):

9/2013-9/2015 Professor of Medicine, Microbiology, Immunology, Molecular Genetics
Director, Kidney and Pancreas Transplant Program
Medical Director, Transplant
University of Kansas (KU)
10/2008-8/2013 Kathy and Harry Jentsch Professor of Medicine
Professor of Surgery and Pharmacology
Chief, Nephrology Division, Department of Medicine
Medical Director, Abdominal Transplant Program, University of Arizona
Vice Chair, Research, Department of Medicine
2006-2017 Adjunct Professor of Medicine, Applied Genomics Center, University of Alberta
2007-2008 Vice Chair Research, Department of Surgery, University of Illinois
1/2006-9/2008 Professor of Medicine, Surgery, Pharmacology
Director, Multi-Organ Transplant Center, University of Illinois at Chicago
2002-2006 Eminent Scholar, University of Florida, Endowed Chair in Medicine, Central Florida Kidney Centers

8/2001-1/2006 Professor of Medicine
Professor of Pharmacology and Therapeutics
Medical Director, Renal and Pancreas Transplantation
University of Florida College of Medicine, Gainesville

2000-2001	Associate Professor of Pharmacology Co-Medical Director, Renal and Pancreas Transplant Programs University of Michigan, Ann Arbor
3/1999-7/2001	Associate Professor with Tenure of Internal Medicine, University of Michigan Co-Director, Renal Transplant Fellowship
9/1997-2/1999	Director of Research/Transplant, Saint Barnabas Medical Center, Livingston, New Jersey
6/1996-8/1997	Assistant Professor of Medicine and Surgery, Director, Transplant Nephrology, University of Texas, Houston
1994-1996	Director, Pharmacology Center Core Lab, Northwestern Memorial Hospital Chicago, Illinois (non academic research position)
9/1993-5/1996	Assistant Professor of Medicine, Northwestern University Medical School, Chicago, Illinois 1991-1996 Adjunct Faculty, Clinical Pharmacology Center, Northwestern University Medical School, Chicago, Illinois (non academic researcher with Dr. Atkinson)
7/1992-8/1993	Associate Director, Immunology, Sandoz Research Institute, Sandoz Pharmaceuticals Corporation, East Hanover, New Jersey (now Novartis Pharmaceuticals)

ADVISORY APPOINTMENTS:

AST/NIH, Endpoints in Transplantation Committee, Multicenter study “Mycophenolate Pharmacokinetic Monitoring”
Steering Committee, International Advisory Committee on development of Myfortic for renal transplantation
Steering Committee, RAD development for renal transplantation
Advisory Board, Development of Bristol Myers Squibb compound LEA29Y
Advisory Board, Early development of Genzyme TNF α compound for renal transplantation
Advisory Board, CellCept® TDM, Roche Laboratories,
Advisory Board (Standing Member), Novartis Experimental and Translational Studies
Advisory Board, (International) Nature Reviews Nephrology
Steering Committee, Progression of Renal Disease in Transplant (USRDS)
Steering Committee, PORT Study
Advisory Board, TransVax, ACMV vaccine technology, Astellas Expert Panel Review
Advisory Board, Transplant genomics Incorporated
Advisory Board, FDA End Points

SCIENTIFIC & ACADEMIC ACTIVITIES:

1994-1996	Pharmacy and Therapeutics Committee, Northwestern University Medical Center, Chicago
1998-1999	Residency Review Committee, Saint Barnabas Medical Center
1998-Present	American Society of Clinical Pharmacology and Therapeutics Renal Section
1999-2002	American Society of Transplant Physicians, Training and Manpower Committee
2000-Present	Ad hoc Journal Reviews, New England Journal of Medicine, American Journal of Kidney Diseases, Journal of the American Society of Nephrology, Kidney International, American Journal of Physiology (Renal), Therapeutic Drug Monitoring, Transplantation, Clinical Pharmacokinetics, American Journal of Transplantation, International Immunopharmacology, Pharmacoeconomics, Drugs & Aging, Nature, Medicine
2002-2004	Deputy Editor, Graft
2002-2007	Editorial Board, Journal of the American Society of Nephrology
2003-2016	Deputy Editor, American Journal of Transplantation
2015-2017	Mayo Clinic Transplant Enterprise Scientific Advisory Board
2015-2017	Director Transplant Research , Mayo Clinic AZ
2017-Present	Executive Editor Transplantation

PATENTS AND TECHNOLOGIES:

1. Immunosuppressive Strategies to Prevent Type I Diabetes Mellitus
Patent Numbers: 60/751,617 & 60/816,659
2. Use of Immunosuppressives to enhance collagen synthesis, Patent pending

TEXT BOOK:

Immunosuppressive Pharmacology: Principles and Practices; Editors: **Kaplan B**, Burkhart G, Lakkis F, Wiley-Blackwell, First Edition, 2012

PEER-REVIEWED PUBLICATIONS:

1. **Kaplan B**. Krumlovsky FA. Phenytoin in end-stage renal disease. *Int J Artif Organs*. 15 (2): 69-70, 1992 Feb.
2. **Kaplan B**. Wang T. Rammohan M. del Greco F. Molteni A. Atkinson AJ Jr. Response to head-up tilt in cramping and noncramping hemodialysis patients. *Int J Clin Pharmacol Ther Toxicol*. 30(5) :173-180, 1992 May
3. Schlueter W. Keilani T. Hizon M. **Kaplan B**. Battle DC. On the mechanism of impaired distal acidification in hyperkalemic renal tubular acidosis: evaluation with amiloride and bumetanide. *J Am Soc Nephrol*. 3(4): 953-964, 1992 Oct.
4. Kaufman DB. **Kaplan B**. Kanwar YS. Abecassis M. Stuart FP. The successful use of tacrolimus (FK506) in a pancreas/kidney transplant recipient with recurrent cyclosporine-associated hemolytic uremic syndrome. *Transplantation*. 59(12): 1737-1739, 1995 Jun 27.
5. **Kaplan B**, Wang Z, Keilani T, Kaufman DB. The specificity of monoclonal fluorescence polarization immunoassay for cyclosporine in recipients of simultaneous pancreas-kidney transplants. *Ther Drug Monit*. 17(5): 499-503, 1995 Oct.
6. Shaw LM, Annesley TM, **Kaplan B**, Brayman KL. Analytic requirements for immunosuppressive drugs in clinical trials. *Ther Drug Monit*. 17(6): 577-583, 1995 Dec.
7. **Kaplan B**. Cooper J. Lager D. Abecassis M. Hepatic infarction in a hemodialysis patient with systemic lupus erythematosus. *Am J Kidney Dis*. 26(5): 785-787, 1995 Nov.
8. **Kaplan B**, Wang Z, Abecassis M, Stuart FP, Kaufman DB. Cyclosporine pharmacokinetics and risk of recurrent rejection in recipients of simultaneous pancreas/kidney transplants. *Ther Drug Monit*. 18(5): 556-561, 1996 Oct.
9. Yedidag EN. Koffron AJ. Mueller KH. **Kaplan B**. Kaufman DB. Fryer JP. Stuart FP. Abecassis M. Acyclovir triphosphate inhibits the diagnostic polymerase chain reaction for cytomegalovirus.. *Transplantation*. 62(2): 238-242, 1996 Jul 27.
10. Shaw L, **Kaplan B**, Kaufman DB. Toxic effects of immunosuppressive drugs: mechanisms and strategies for controlling them. *Clin Chem*. 42(8 Pt 2): 1316-1321, 1996 Aug.
11. **Kaplan B**, Wang Z, Abecassis MM, Fryer JP, Stuart FA, Kaufman DB. Frequency of hyperkalemia in recipients of simultaneous pancreas/kidney transplants with bladder drainage. *Transplantation*. 62(8): 1174-1175, 1996 Oct 27.
12. Abecassis MM. Koffron AJ. **Kaplan B**. Buckingham M. Muldoon JP. Cribbins AJ. Kaufman DB. Fryer JP. Stuart J. Stuart FP. Role of PCR in the diagnosis and management of CMV in solid organ recipients: what is the predictive value for the development of disease and should PCR be used to guide antiviral therapy? *Transplant Proc*. 28(6 Suppl 2): 2-4, 1996 Dec.

13. **Kaplan B**, Meier-Kriesche HU, Napoli K, Kahan BD. A limited sampling strategy for estimating Sirolimus area-under-the-concentration curve. *Clin Chem*. 43(3): 539-540, 1997 Mar.
14. Adachi J, Grimm E, Johnson P, Uthman M, **Kaplan B**, Rakita R. Human granulocytic ehrlichiosis in a renal transplant patient: case report and review of the literature. *Transplantation*. 64(8): 1139-1142, 1997 Oct 27.
15. Fryer JP, Blondin B, Stadler C, Ivancic D, Ratmer U, **Kaplan B**. Inhibition of human serum mediated lysis of porcine endothelial cells using a novel peptide which blocks C1Q binding to xenoantibody. *Transplant Proc*. 29(1-2): 883, 1997 Feb-Mar.
16. **Kaplan B**, Meier-Kriesche HU, Napoli KL, Kahan BD. The effects of relative timing of sirolimus and cyclosporine microemulsion formulation coadministration on the pharmacokinetics of each agent. *Clin Pharmacol Ther*. 63(1): 48-53, 1998 Jan.
17. Shaw L, **Kaplan B**, Brayman KL. Prospective investigations of concentration – clinical response for immunosuppressive drugs provide the scientific basis for therapeutic drug monitoring. *Clin Chem*. 44(2): 381-387, 1998 Feb.
18. **Kaplan B**, Gruber SA, Nallamathou R, Katz SM, Shaw LM. Decreased protein binding of mycophenolic acid associated with leukopenia in a pancreas transplant recipient with renal failure. *Transplantation*. 65(8): 1127-1129, 1998 Apr 27.
19. **Kaplan B**, Friedman G, Jacobs M, Viscuso R, Lyman N, DeFranco P, Bonomini B, Mulgaonkar SP. Potential interaction of troglitazone and cyclosporine. *Transplantation*. 65(10): 1399-1400, 1998 May 27.
20. Meier-Kriesche HU, **Kaplan B**, Brannan P, Kahan BD, Portman RJ. A limited sampling strategy for the estimation of eight-hour neoral areas under the curve in renal transplantation. *Ther Drug Monit*. 20(4): 401-407, 1998 Aug.
21. **Kaplan B**, Wang T, Henthorn T, Mujais S. Evaluations of urea kinetics using a stable isotope methodology and pharmacokinetic modeling. *Artif Organs*. 23(1): 44-50, 1999 Jan.
22. **Kaplan B**, Lown K, Craig R, Abecassis M, Kaufman D, Leventhal J, Stuart F, Meier-Kriesche HU, Fryer J. Low bioavailability of cyclosporine microemulsion and tacrolimus in a small bowel transplant recipient: possible relationship to intestinal p-glycoprotein activity. *Transplantation*. 67(2): 333-335, 1999 Jan 27.
23. **Kaplan B**, Meier-Kriesche HU, Napoli K, Kahan BD. Correlation between pretransplantation test dose cyclosporine pharmacokinetic profiles and posttransplantation sirolimus blood levels in renal transplant recipients. *Ther Drug Monit*. 21(1): 44-49, 1999 Feb.
24. Meier-Kriesche HU, Alloway R, Gaber AO, Canafax D, and **Kaplan B**. A limited sampling strategy for the estimation of 12-hour SangCya and neoral AUCs in renal transplant recipients. *J Clin Pharmacol*. 39(2): 166-171, 1999 Feb.
25. **Kaplan B**, Meier-Kriesche HU, Friedman G, Mulgaonkar S, Gruber S, Korecka M, Brayman K, and Shaw L. The effect of renal insufficiency on mycophenolic acid protein binding. *J Clin Pharmacol*. 39(7): 715-720, 1999 Jul.
26. **Kaplan B**, Meier-Kriesche HU, Jacobs MG, Friedman G, Bonomini L, DeFranco P, Gelfand E, Mulgaonkar S. Prevalence of cytomegalovirus in the gastrointestinal tract of renal transplant recipients with persistent abdominal pain. *Am J Kidney Dis*. 34(1): 65-68, 1999 Jul.
27. Meier-Kriesche HU, Friedman G, Mulgaonkar S, Jacobs M, and **Kaplan B**. Infectious complications in geriatric renal transplant patients: comparison of two immunosuppressive protocols. *Transplantation*. 68(10): 1496-1502, 1999 Nov 27.

28. Meier-Kriesche HU, Vaghela M, Thambuganipalle R, Friedman G, Jacobs M, **Kaplan B**. Effect of body mass index on long-term renal allograft survival. *Transplantation*. 68(9): 1294-1297, 1999 Nov. 15.
29. **Kaplan B**. Pharmacokinetics and pharmacodynamics of immunosuppressive agents. *Graft* 2: 1999.
30. Meier-Kriesche HU, Shaw LM, Korecka M, **Kaplan B**. Pharmacokinetics of mycophenolate acid in renal insufficiency. *Ther Drug Monit* 22(1): 27-30, 2000 Feb
31. Shaw L, **Kaplan B**, Korecka M, Denofrio D, Brayman K. Pharmacokinetics and concentration control studies with mycophenolate mofetil in adults after transplantation. *Ther Drug Monit*. 22(1): 14-19, 2000 Feb.
32. Meier-Kriesche HU, Ojo A, Hanson J, Cibrik D, Lake K, Agodoa LY, Leichtman A, **Kaplan B**. Increased immunosuppressive vulnerability in elderly renal transplant recipients. *Transplantation*. 69(5): 885-889, 2000 Mar 15.
33. **Kaplan B**, Meier-Kriesche HU, Vaghela M, Friedman G, Mulgaonkar S, Jacobs M. Withdrawal of mycophenolate mofetil in stable renal transplant recipients. *Transplantation*. 69(8): 1726-1728, 2000 Apr 27.
34. **Kaplan B**, Cheema A, Friedman G, Shah N, Bonomini L, Mulgaonkar S, Nambi S, De Franco P. Unmasking of primary hyperaldosteronism by renal transplantation. *Transplantation*. 69(7): 1503-1505, 2000 Apr 15.
35. Friedman GS, Wik D, Silva L, Abdou JC, Meier-Kriesche HU, **Kaplan B**, Bonomini L, DeFranco P, Lyman N, Mulgaonkar S., Jacobs M. Allograft loss in renal transplant patients with Fabry's disease and activated protein C resistance. *Transplantation*. 69(10): 2099-2102, 2000 May 27.
36. Whang M, Katz L, Ongcapin E, Geffner S, Friedman GS, Mulgaonkar SP, **Kaplan B**. Nephrogenic adenomas occurring in a patient with simultaneous kidney-pancreas transplant. *Urology*, 55(6): 949, 2000 Jun 1.
37. Meier-Kriesche HU, Palenkar SS, Friedman GS, Mulgaonkar SP, Goldblat MV, **Kaplan B**. Efficacy of Daclizumab in African-American and Hispanic renal transplant population. *Transpl Int*. 13(2): 142-145, 2000.
38. Ojo A, Meier-Kriesche HU, Friedman G, Hanson J, Cibrik D, Leichtman AB, **Kaplan B**. Excellent outcome of renal transplantation in patients with Fabry's disease. *Transplantation*. 69(11): 2337-2339, 2000 Jun 15
39. Meier-Kriesche HU, **Kaplan B**. Toxicity and efficacy of Sirolimus: relationship to whole blood concentrations. *Clin Ther*. 22 (Suppl B): B93-B100, 2000.
40. Ojo AO, Meier-Kriesche HU, Hanson JA, Leichtman AB, Cibrik D, Magee JC, Wolfe RA, Agodoa LY and **Kaplan B**. Mycophenolate mofetil reduces late renal allograft loss independent of acute rejection. *Transplantation*. 69(11): 2405-2409, 2000 Jun 15.
41. Meier-Kriesche HU, Ojo AO, Cibrik DM, Hanson JA, Leichtman JC, Magee JC, Port FK, **Kaplan B**. Relationship of recipient age and development of chronic allograft failure. *Transplantation*. 70(2): 306-310, 2000 Jul 27.
42. Gruber SA, Katz S, **Kaplan B**, Clark J, Chen P, El-Sabrou R, Kerman R. Initial results of solitary pancreas transplants performed without regard to donor/recipient HLA mismatching. *Transplantation*. 70(2): 388-391, 2000 Jul 27.
43. Meier-Kriesche HU, Ojo A, Hanson J, Cibrik D, Magee J, Leichtman A **Kaplan B**. African-American renal transplant recipients experience decreased risk of death due to infection: possible implications for immunosuppressive strategies. *Transplantation*. 70(2): 375-379, 2000, July 27.
44. Meier-Kriesche HU. Port FK. Ojo AO. Rudich SM. Hanson JA. Cibrik DM. Leichtman AB. **Kaplan B**. Effect of waiting time on renal transplant outcome. *Kidney Int*. 58(3): 1311-1317, 2000 Sep.

45. Meier-Kriesche HU, Ojo A, Hanson J, Cibrik D, Punch J, Leichtman A **Kaplan B**. Increased impact of acute rejection on chronic allograft failure in recent era. *Transplantation*. 70(7): 1098-1100, 2000 Oct 15.
46. Meier-Kriesche HU, Kaza H, Palekar S, Friedman G, Mulgaonkar S, Ojo A, **Kaplan B**. The effect of Daclizumab in a high-risk renal transplant population. *Clin Transplant*. 14(5): 509-513, 2000 Oct.
47. Meier-Kriesche HU, Punch JD, Leichtman AB, Cibrik D, Ojo A, Hanson J **Kaplan B** Effect of mycophenolate mofetil on long-term outcomes in African American renal transplant recipients:. *J Am Soc Nephrol*. 2000 Dec;11(12):2366-2370. doi: 10.1681/ASN.V11122366
48. Shaw LM, **Kaplan B**, Brayman KL. Advances in therapeutic drug monitoring for immunosuppressants: a review of sirolimus. Introduction and overview. *Clin Ther*. 22 Suppl B: (B1-B13), 2000.
49. Ojo AO. Meier-Kriesche HU. Hanson JA. Leichtman A. Magee JC. Cibrik D. Wolfe RA. Port FK. Agodoa L. Kaufman DB. **Kaplan B**. The impact of simultaneous pancreas-kidney transplantation on long-term patient survival. *Transplantation*. 71(1): 82-90, 2001 Jan 15.
50. Ojo AO. Meier-Kriesche HU. Hanson JA. Leichtman A. Magee JC. Cibrik D. Wolfe RA. Port FK. Agodoa L. Kaufman DB. **Kaplan B**. Type of transplant and outcome in patients with diabetes mellitus and end stage renal disease. *Transplantation*. 71(1) 82-90, 2001 Jan. 15.
51. Okechukwu N, Meier-Kriesche HU, Armstrong D, Campbell D, Gerbeau C, **Kaplan B**. Removal of Basiliximab by plasmapheresis. *Am J Kidney Dis*. 37(1): E11, 2001 Jan.
52. Kovarik J, Kahan,B, **Kaplan B** Lorber M, Winkler M , Roouily M, Gerbeau C, Cambon N, Boger B. Rordorf C. Everolimus Phase Study Group. Longitudinal pharmacokinetics of everolimus and its influence on cyclosporine in de novo renal transplant recipients. *Clin Pharmacol Ther*. 69(1): 48-56, 2001 Jan.
53. Meier-Kriesche HU, Ojo AO, Leichtman AB, Magee JC, Rudich SM, Hanson JA, Cibrik DM. **Kaplan B**. Interaction of mycophenolate mofetil and HLA matching on renal allograft survival. *Transplantation*. 71(3): 398-401, 2001 Feb 15.
54. .Ojo AO. Meier-Kriesche HU. Arndorfer JA. Leichtman AB. Magee JC. Cibrik DM. Wolfe RA. Port FK. Agodoa L. Kaufman DB. **Kaplan B**. Long-term benefit of kidney-pancreas transplants in type 1 diabetics. *Transplant Proc*. 33(1-2): 1670-1672, 2001 Feb-Mar.
55. Meier-Kriesche HU, Ojo AO, Port FK. Magee JC., Leichtman, AB. Punch J.D. **Kaplan B**. Recipient age as independent risk factor for chronic renal allograft failure. *Transplant Proc* 2001 33(1-2): 1113-1114, 2001 Feb-Mar.
56. Meier-Kriesche HU, Ojo AO, Hanson JA, Leichtman A.B, Lake K, Cibrik DM, Punch J.D, **Kaplan B**. Need for individualized immunosuppression in elderly renal transplant recipients. *Transplant Proc* 33(1-2): 1190-1191, 2001 Feb-Mar.
57. Meier-Kriesche H, Ojo AO, Arndorfer JA, Magee JC, Cibrik DM, Leichtman AB, Campbell DA, **Kaplan B**. Mycophenolate mofetil decreases the risk for chronic renal allograft failure. *Transplant Proc* 33(1-2): 1005-1006, 2001 Feb-Mar.
58. Meier-Kriesche HU, Port FK, Ojo AO, Leichtman AB, Rudich SM, Arndorfer JA, Punch JD, **Kaplan B**. Deleterious effect of waiting time on renal transplant outcome. *Transplant Proc*. 33(1-2):1204-1206, 2001 Feb-Mar.
59. Arndorfer JA, Meier-Kriesche HU, Ojo AO, Gruber SA, Cibrik DM, Lake KD, **Kaplan B**, Leichtman AB. Time to first graft loss as a risk factor for second renal allograft loss. *Transplant Proc*. 33(1-2):1188-1189, 2001 Feb-Mar.

60. Meier-Kriesche HU, Ojo AO, Leavey SF, Hanson JA, Leichtman AB, Magee JC, Cibrik DM, **Kaplan B**. Gender differences in the risk for chronic allograft failure. *Transplantation*. 71(3): 429-432, 2001 Feb 15.
61. Ojo AO, Hanson JA, Meier-Kriesche H, Okechukwu CN, Wolfe RA, Leichtman AB, Agodoa LY, **Kaplan B**, Port FK. Survival in recipients of marginal cadaveric donor kidneys compared with other recipients and wait-listed transplant candidates. *J Am Soc Nephrol*. 2001 Mar;12(3):589-597. doi:10.1681/ASN.V123589
62. Meier-Kriesche HU, Ojo A, Hanson J, **Kaplan B**. Exponentially increased risk of infectious death in older renal transplant recipients: a comparison of transplanted and wait-listed end stage renal disease patients. *Kidney Int* . 59(4): 1539-1543, 2001 Apr.
63. Kovarik JM, Pescovitz MD, Sollinger HW, **Kaplan B**, Legendre C, Salmela K, Book BK, Gerbeau C, Girault D, Somberg K. Differential influence of azathioprine and mycophenolate mofetil on the disposition of basiliximab in renal transplant patients. *Clin Transplant*. 15(2): 123-130, 2001 Apr.
64. Mathis AS, DiRenzo T, Friedman G, **Kaplan B**, Adamson R. Sex and ethnicity may chiefly influence the interaction of fluconazole with calcineurin inhibitors. *Transplantation*. 71(8): 1069-1075, 2001, Apr 27.
65. Kahan BD, **Kaplan B** , Lorber MI, Winkler M, Cambon N , Boger RS: RAD in de-novo renal transplantation: comparison of three doses on the incidence and severity of acute rejection. *Transplantation*. 71(10): 1400-1406, 2001 May 27.
66. Polsky D, Weinfurt K, **Kaplan B**, Kim J, Fastneau J, Schulman K. An economic assessment of simulect vs antithymocyte globulin immunoprophylaxis. *Nephrol Dial Transplant*. 16(5):1028-1033, 2001 May.
67. Meier-Kriesche HU, Ojo A, Port F, Arndorfer J Cibrik D, **Kaplan B**: Survival improvement among patients with end-stage renal disease: trends over time for transplant patients and wait-listed patients. *J Am Soc Nephrol*. 2001 Jun;12(6):1293-1296. doi: 10.1681/ASN.V1261293
68. Meier-Kriesche HU, Ojo A, Hanson J **Kaplan B**. Hepatitis C and outcomes in renal transplantation. *Transplantation*. 72(2): 241-244, 2001 Jul 27.
69. Yamani A, Myers-Powell B, Whitcup SM, Cohen SB, Kanter ED, **Kaplan B**, Zarbin MA. Visual loss after renal transplantation. *Retina* . 21(5): 553-559., 2001 Oct.
70. Sollinger H, **Kaplan B**, Pescovitz M, Philosophie B, Roza A, Brayman K, Somberg K. Basiliximab versus antithymocyte globulin for prevention of acute renal allograft rejection. *Transplantation*. 72(12): 1915-1919, 2001 Dec 27.
71. Meier-Kriesche HU, **Kaplan B**. Immunosuppression in elderly renal transplant recipients: are current regimens too aggressive? *Drugs Aging*. 18(10):751-759, 2001.
72. Cibrik DM, **Kaplan B**, Meier-Kriesche HU. Role of anti-interleukin-2 receptor antibodies in kidney transplantation. *BioDrugs*. 15(10): 655-666, 2001.
73. Meier-Kriesche HU, Ojo AO, Leavey S, Cibrik D, Arndorfer JA, Leichtman AB, Punch J, Armstrong D **Kaplan B**. Differences in etiology of graft loss in female renal transplant recipients. *Transplant Proc*. 33(1-2): 1288-1290, 2001 Feb-Mar.
74. Meier-Kriesche HU, Ojo AO, Hanson JA **Kaplan B**. Hepatitis C antibody status and outcomes in renal transplant recipients. *Transplantation*. 72(2): 241-244, 2001 Jul 27
75. Friedman GS, Meier-Kriesche HU, **Kaplan B**, Mathis AS, Bonomini L, Shah N, DeFranco P, Jacobs M, Mulgaonkar S, Geffner S, Lyman N, Paraan C, Walsh C, Belizaire W, Tshibaka M. Hypercoagulable states in renal transplant candidates: impact of anticoagulation upon incidence of renal allograft thrombosis. *Transplantation*. 72(6): 1073-1078, 2001 Sep 27.

76. Matalon A, Markowitz GS, Joseph RE, Cohen DJ, Saal SD, **Kaplan B**, D'Agati VD, Appel GB. Plasmapheresis treatment of recurrent FSGS in adult renal transplant recipients. *Clin Nephrol.* 56(4): 271-278, 2001 Oct.
77. Meier-Kriesche HU, **Kaplan B**. Immunosuppression in elderly renal transplant recipients: are current regimens too aggressive? *Drugs Aging.* 18(10): 751-759, 2001.
78. Meier-Kriesche HU, **Kaplan B**. Death after graft loss: a novel endpoint for renal transplantation. *Transplant Proc.* 33(7-8): 3405-3406, 2001 Nov-Dec.
79. Meier-Kriesche H-U, **Kaplan B**. Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared to Sandimmune. *Am J Transplant.* 2002 Jan;2(1):100-1004. doi: 10.1034/j.1600-6143.2002.020116.x.
80. Meier-Kriesche HU, Cibrik DM, Ojo AO, Hanson JA, Magee J, Rudich S, Leichtman AB, **Kaplan B**. Interaction between donor and recipient age in determining the risk for chronic renal allograft failure. *J Am Geriatr Soc.* 2002 Jan;50(1):14-17. doi: 10.1046/j.1532-5415.2002.50002.x.
81. Meier-Kriesche HU, Arndorfer JA, **Kaplan B**. The Impact of Body Mass Index on Renal Transplant Outcomes: A Significant Independent Risk Factor for Graft Failure and Patient Death. *Transplantation.* 15;73(1):70-4, 2002 Jan.
82. Meier-Kriesche HU, **Kaplan B**. Cyclosporine microemulsion and tacrolimus are associated with decreased chronic allograft failure and improved long-term graft survival as compared with sandimmune. *Am J Transplant.* 2(1):100-104, 2002 Jan.
83. **Kaplan B**, Srinivas T, Meier-Kriesche HU. Factors associated with long-term renal allograft survival. *Ther Drug Monit.* 2002 Feb;24(1):36-39. doi: 10.1097/00007691-200202000-00007
84. Kovarik JM, **Kaplan B**, Silva HT, Kahan BD, Dantal J, Vitko S, Boger R, Rordorf C. Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range. *Transplantation.* 2002 Mar 27;73(6):920-925. doi: 10.1097/00007890-200203270-00016
85. Meier-Kriesche HU, Arndorfer JA, **Kaplan B**. Association of antibody induction with short and long-term cause-specific mortality in renal transplant recipients. *J Am Soc Nephrol.* 2002 Mar;13(3):769-772. doi: 10.1681/ASN.V133769
86. Srinivas TR, Meier-Kreische HU, **Kaplan B**, Bennett WM. Response to "Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared with lisinopril". *Transplantation.* 2002 Jul 15;74(1):139; author reply 139-40. doi: 10.1097/00007890-200207150-00016
87. **Kaplan B**, Meier-Kriesche HU. Mortality risk assessment after renal transplantation. *Clin Transpl.* 2002:131-136. PMID: 12971442
88. **Kaplan B**. Steroid-sparing immunosuppression: Historical View of Steroid Withdrawal in *Transplantation.* 2002.
89. Cibrik DM, **Kaplan B**, Arndorfer JA, Meier-Kriesche HU. Renal allograft survival in patients with oxalosis. *Transplantation.* 2002 Sep 15;74(5):707-710. doi: 10.1097-00007890-200209150-00020
90. **Kaplan B**, Meier-Kriesche HU. Death after graft loss: an important late study endpoint in kidney transplantation. *Am J Transplant.* 2002 Nov;2(10):970-974. doi: 10.1034/j.1600-6143.2002.21015.x.

91. Meier-Kriesche HU, **Kaplan B**. Waiting time on dialysis as the strongest modifiable risk factor for renal transplant outcomes: a paired donor kidney analysis. *Transplantation*. 2002 Nov;74(10):1377-1381. doi: 10.1097/00007890-200211270-00005
92. Rudich SM, **Kaplan B**, Magee JC, Arenas JD, Punch JD, Kayler LK, Merion RM, Meier-Kriesche HU. Renal transplantations performed using non-heart-beating organ donors: going back to the future? *Transplantation*. 2002 Dec;74(12):1715-1720. doi: 10.1097/00007890-200212270-00013
93. Srinivas TR, Meier-Kriesche HU, **Kaplan B**. Everolimus in renal transplantation. *Curr Opin Organ Transplant*. 7(4): 359-365, 2002 Dec.
94. Meier-Kriesche HU, Steffen BJ, Hochberg AM, Gordon RD, Liebman MN, Morris JA, **Kaplan B**. Long-term use of mycophenolate mofetil is associated with a reduction in the incidence and risk of late rejection. *Am J Transplant*. 2003 Jan;3(1):68-73. doi: 10.1034/j.1600-6143.2003.30112.x.
95. Cibrik DM, **Kaplan B**, Campbell DA, Meier Kriesche HU. Renal allograft survival in transplant recipients with focal segmental glomerulosclerosis. *Am J Transplant*. 2003 Jan;3(1):64-67. doi: 10.1034/j.1600-6143.2003.30111.x.
96. Meier-Kriesche HU, Steffen BJ, Hochberg AM, Gordon RD, Liebman MN, Morris JA, **Kaplan B**. Mycophenolate mofetil vs azathioprine therapy is associated with a significant protection against long-term renal allograft function deterioration. *Transplantation*. 2003 Apr;75(8): 1341-1346. doi: 10.1097/01.TP.0000062833.14843.4B
97. Meier-Kriesche HU, Baliga R, **Kaplan B**. Decreased renal function is a strong risk factor for cardiovascular death after renal transplantation. *Transplantation*. 2003 Apr;75(8):1291-1295. doi: 10.1097/01.TP.0000061620.03327.E2
98. Kovarik JM, **Kaplan B**, Silva HT, Kahan BD, Dantal J, McMahon L, Berthier S, Hsu CH, Rordorf C. Pharmacokinetics of an everolimus-cyclosporine immunosuppressive regimen over the first 6 months after kidney transplantation. *Am J Transplant*. 2003 May;3(5):606-613. doi: 10.1034/j.1600-6143.2003.00107.x.
99. **Kaplan B**, Schold J Meier-Kriesche HU. Overview of large database analysis in renal transplantation. *Am J Transplant*. 2003 Sep;3(9):1052-1056. doi: 10.1034/j.1600-6143.2003.00193.x.
100. **Kaplan B**, Schold JD, Meier-Kriesche HU. Long-term graft survival with neoral and tacrolimus: a paired kidney analysis. *J Am Soc Nephrol*. 2003 Nov;14(11):2980-2984. doi: 10.1097/01.asn.0000095250.92361.d5
101. **Kaplan B**, Schold J, Meier-Kriesche HU. Poor predictive value of serum creatinine for renal allograft loss. *Am J Transplant*. 2003 Dec;3(12):1560-1565. doi: 10.1046/j.1600-6135.2003.00275.x.
102. Srinivas TR, **Kaplan B**, Meier-Kriesche HU. Mycophenolate Mofetil in solid organ transplantation. *Expert Opinion in Pharmacother*. 2003 Dec;4(12):2325-45. doi: 10.1517/14656566.4.12.2325.
103. Kapturczak MH, Meier-Kriesche HU, **Kaplan B**. Pharmacology of calcineurin antagonists. *Transplant Proc*. 36(2Suppl): 25S-32S, 2004 Mar.
104. Meier-Kriesche HU, Schold JD, Srinivas TR, **Kaplan B**. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. *Am J Transplant*. 2004 Mar;4(3): 378-383. doi: 10.1111/j.1600-6143.2004.00332.x.
105. Curtis JJ, **Kaplan B**. Transplant immunosuppressive drug trials on trial. *Am J Transplant*. 2004 May;4(5): 671-672. doi: 10.1111/j.1600-6143.2004.00474.x.
106. Meier-Kriesche HU, Schold JD, **Kaplan B**. Long-term renal allograft survival: have we made significant progress or is it time to rethink our analytic and therapeutic strategies? *Am J Transplant*. 2004 Aug;4(8):1289-1295. doi: 10.1111/j.1600-6143.2004.00515.x.

107. Meier-Kriesche H-U, Schold JD, Srinivas TR, Reed A, **Kaplan B**. Kidney transplantation halts cardiovascular disease progression in patients with end-stage renal disease. *Am J Transplant*. 2004 Oct;4(10): 1662-1668. doi: 10.1111/j.1600-6143.2004.00573.x.
108. **Kaplan B**, Schold J, Srinivas T, Womer K, Foley DP, Patton P, Howard R, Meier-Kriesche HU. Effect of sirolimus withdrawal in patients with deteriorating renal function. *Am J Transplant*. 2004 Oct;4(10):1709-1712. doi: 10.1111/j.1600-6143.2004.00569.x.
109. Halloran PF, Langone AJ, Helderman JH, **Kaplan B**. Assessing long-term nephron loss: is it time to kick the CAN grading system? *Am J Transplant*. 2004 Nov;4(11):1729-1730. doi: 10.1111/j.1600-6143.2004.00662.x.
110. Meier-Kriesche HU, Morris JA, Chu AH, Steffen BJ, Gotz VP, Gordon RD, **Kaplan B**. Mycophenolate mofetil vs azathioprine in a large population of elderly renal transplant patients. *Nephrol Dial Transplant*. 2004 Nov;19(11): 2864-2869. doi: 10.1093/ndt/gfh445.
111. Smith WD, Hatton RC, Fann AL, Baz MA, **Kaplan B**. Evaluation of drug interaction software to identify alerts for transplant medications. *Ann Pharmacother*. 2004 Dec;39(1): 45-50. doi: 10.1345/aph.1E331
112. **Kaplan B**, Meier-Kriesche HU. Renal transplantation: a half century of success and the long road ahead. *J Am Soc Nephrol*. 2004 Dec;15(12):3270-3271. doi: 10.1097/01.ASN.00000146569.59482.8C
113. Meier-Kriesche HU, Steffen B, Chu A, Loveland J, Gordon RD, Morris J, **Kaplan B**. Sirolimus with neoral versus mycophenolate mofetil with neoral is associated with decreased renal allograft. *Am J Transplant*. 2004 Dec;4(12): 2058-2066. doi: 10.1111/j.1600-6143.2004.00624.x.
114. Womer KL, Meier-Kriesche HU, **Kaplan B**. Which calcineurin inhibitor? *Eur J Hosp Pharm*. 10(5): 15-16, 2004.
115. Srinivas TR, Meier-Kriesche HU, **Kaplan B**. Pharmacokinetic principles of immunosuppressive drugs. *Am J Transplant*. 2005 Feb;5(2):207-217. doi: 10.1111/j.1600-6143.2005.00748.x.
116. Meier-Kriesche HU, Schold JD, **Kaplan B**. Preservation of long-term renal allograft survival: a challenge for the years to come. *Am J Transplant*. 5(3): 632-633, 2005 Mar.
117. Schold JD, **Kaplan B**, Baliga RS, Meier-Kriesche HU. The broad spectrum of quality in deceased donor kidneys. *Am J Transplant*. 2005 Apr;5(4 Pt 1):757-765. doi: 10.1111/j.1600-6143.2005.00770.x.
118. Halloran PF, **Kaplan B**. Evolving issues in clinical research. *Am J Transplant*. 2005 Apr;5(4 Pt 1):637-638. doi: 10.1111/j.1600-6143.2005.00881.x.
119. Meier-Kriesche HU, Schold JD, Gaston RS, Wadstrom J, **Kaplan B**. Kidneys from deceased donors: maximizing the value of a scarce resource. *Am J Transplant*. 2005 Jul;5(7):1725-1730. doi: 10.1111/j.1600-6143.2005.00923.x.
120. Schold JD, **Kaplan B**, Howard RJ, Reed AI, Foley DP, Meier-Kriesche HU. Are we frozen in time? Analysis of the utilization and efficacy of pulsatile perfusion in renal transplantation. *Am J Transplant*. 2005 Jul;5(7):1681-1688. doi: 10.1111/j.160-6142.2005.00910.x.
121. **Kaplan B**, Meier-Kriesche HU, Minnick P, Bastien MC, Sechaud R, Yeh CM, Balez S, Picard F, Schmouder R. Randomized calcineurin inhibitor cross over study to measure the pharmacokinetics of co-administered enteric-coated mycophenolate sodium. *Clin Transplant*. 2005 Aug;19(4): 551-558. doi: 10.1111/j.1399-0012.2005.00387.x.
122. Meier-Kriesche HU, Schold JD, Srinivas TR, Howard RJ, Fujita S, **Kaplan B**. Sirolimus in combination with tacrolimus is associated with worse renal allograft survival compared to mycophenolate mofetil combined with

- tacrolimus. *Am J Transplant.* 2005 Sep;5(9):2273-2280. doi: 10.1111/j.1600-6143.2005.01019.x.
123. Schold JD, **Kaplan B**, Chumbler NR, Howard RJ, Srinivas TR, Ma L, Meier-Kriesche HU. Access to quality: evaluation of the allocation of deceased donor kidneys for transplantation. *J Am Soc Nephrol.* 2005 Oct;16(10):3121-3127. doi: 10.1681/ASN.2005050517
 124. Womer KL, Peng R, Patton PR, Murawski MR, Bucci M, Kaleem A, Schold J, Efron PA, Hemming AW, Srinivas TR, Meier-Kriesche HU, **Kaplan B**, Clare-Salzler MJ. The effects of renal transplantation on peripheral blood dendritic cells. *Clin Transplant.* 2005 Oct;19(5):659-667. doi: 10.1111/j.1399-0012.2005.00405.x
 125. Srinivas TR, **Kaplan B**, Schold JD, Meier-Kriesche HU. The impact of mycophenolate mofetil on long term outcomes in kidney transplantation. *Transplantation.* 2005 Oct 15;80(2 Suppl):S211-20. doi: 10.1097/01.tp.0000186379.15301.e5
 126. Halloran P, Reeve J, **Kaplan B**. Lies, damn lies, and statistics: the perils of the P value. *Am J Transplant.* 6(1): 10-11, 2006 Jan.
 127. Womer KL, Meier-Kriesche HU, Patton PR, Dibadj K, Bucci CM, Foley D, Fujita S, Croker BP, Howard RJ, Srinivas TR, **Kaplan B**. Preemptive retransplantation for BK virus nephropathy: successful outcome despite active viremia. *Am J Transplant.* 6(1): 209-213, 2006 Jan.
 128. Schaefer HM, **Kaplan B**, Helderman JH. Mortality after kidney transplantation: what lessons can we learn from regional and country variation? *Am J Transplant.* 6(1): 3-4, 2006 Jan.
 129. Mekeel K, Meier-Kriesche H-U, **Kaplan, B**. Are we making progress in kidney transplantation? *Curr Opin Organ Transplant.* 11(1): 1-6, 2006 Feb.
 130. Ehlers SL, Rodrigue JR, Patton PR, Lloyd-Turner J, **Kaplan B**, Howard RJ. Treating tobacco use and dependence in kidney transplant recipients: development and implementation of a program. *Prog Transplant.* 2006 Mar;16(1) 33-37. PMID: 16676672
 131. Srinivas TR, Schold JD, Womer KL, **Kaplan B**, Howard RJ, Bucci CM, Meier-Kriesche HU. Improvement in hypercalcemia with cinacalcet after kidney transplantation. *Clin J Am Soc Nephrol.* 2006 Mar;1(2):323-6. doi: 10.2215/CJN.00500705
 132. Van Gelder,T, Meur YL, Shaw LM, Oellerich M, Holt DW, **Kaplan B**, Kuypers D, Meiser B Mamelock RD. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. *Ther Drug Monit.* 28 (2): 145-154, 2006 Apr.
 133. Van Gelder T, Le Meur Y, Shaw LM, Oellerich M, DeNofrio D, Holt C, Holt DW, **Kaplan B**, Kuypers D, Meiser B, Toenshoff B, Mamelok RD. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. *Ther Drug Monit.* 2006 Apr;28(2):145-54. doi: 10.1097/01.ftd.0000199358.80013.bd
 134. **Kaplan B**. Overcoming barriers to long-term graft survival. *Am J Kidney Dis.* 2006 Apr;47(4 Suppl 2):S52-S64. doi: 10.1053/j.ajkd.2005.12.044
 135. Rodrigue JR, Widows MR, Guenther R, Howard RJ, Newman R, **Kaplan B**, Howard RJ. The expectancies of living kidney donors: do they differ as a function of relational status and gender? *Nephrol Dial Transplant.* 2006 Jun;21(6):1682-1688. doi: 10.1093/ndt/gfl024.
 136. Rodrigue JR, Cross NJ, Newman RC, Widows MR, Guenther R, **Kaplan B**, Morgan MA, Howard RJ. Patient reported outcomes for open versus laparoscopic living donor nephrectomy. *Prog Transplant.* 2006 Jun;16(2): 162-169. PMID: 16789708
 137. Mehra M, Uber P, **Kaplan B**. Immunosuppression in cardiac transplantation: science, common sense and the heart of the matter. *Am J Transplant.* 6(6): 1243-1245, 2006 Jun.

138. **Kaplan B** Kirk A. Tacrolimus and sirolimus: when bad things happen to good drugs. *Am J Transplant.* 6(7): 1501-1502, 2006 Jul.
139. Howard, DH, **Kaplan B.** Do report cards influence hospital choice? The case of kidney transplantation. *Inquiry.* 2006 Summer;43(2):150-159. doi: 10.5034/inquirtjml_43.2.150.
140. Lansang MC, Ma L, Schold JD, Meier-Kriesche HU, **Kaplan B.** The relationship between diabetes and infectious hospitalizations in renal transplant recipients. *Diabetes Care.* 2006 Jul;29(7):1659-1660. doi: 10.2337/dc05-2412
141. **Kaplan B.** Enteric-coated mycophenolate sodium (myfortic®) – An overview of current and future use in transplantation. *Drugs* 66(Suppl 2): 1-8, 2006.
142. Feng S, Barr M, Roberts J, Oberbauer R and **Kaplan B.** Developments in clinical islet, liver thoracic, kidney and pancreas transplantation in the last 5 years. *Am J Transplant.* 6(8): 1759-1767, 2006 Aug.
143. **Kaplan B.** Mycophenolic acid trough level monitoring in solid organ transplant recipients treated with mycophenolate mofetil: association with clinical outcome. *Curr Med Res Opin.* 2006 Dec;22(12):2355-2364. doi: 10.1185/030079906X148481.
144. Jeong H., **Kaplan B.** Therapeutic monitoring of mycophenolate mofetil. *Clin J Am Soc Nephrol.* 2007 Jan;2(1): 184-191. doi: 10.2215/CJN.02860806
145. **Kaplan B,** Gangemi A, Oberholzer J, Sankary H and Bennediti E. Successful rescue of refractory, severe antibody mediated rejection with splenectomy. *Transplantation.* 2007 Jan 15;83(1):99-100. doi: 10.1097/01.TP.0000243739.31440.2b
146. Rodrigue JR, Cornell DL, Lin JK, **Kaplan B,** Howard RJ. Increasing live donor kidney transplantation: a randomize controlled trial of a home-based educational intervention. *Am J Transplant.* 7(2): 394-401, 2007 Feb.
147. **Kaplan B,** Williams R. Organ donation: the gift, the weight and the tyranny of good acts. *Am J Transplant.* 7(3): 497-498, 2007 Mar.
148. **Kaplan B,** Budde K. Lessons from the CAESAR Study: calcineurin inhibitors--can't live with them and can't live without them. *Am J Transplant.* 7(3): 495-496, 2007 Mar.
149. Beier UH, **Kaplan B,** Setty S, Samuel S, Mathew AV, Oberholzer J, Benedetti E, John E. Electrolyte imbalances in pediatric living related small bowel transplantation. *Transplantation.* 2008 Jan 27;85(2):217-23. doi: 10.1097/TP.0b013e31816025b4,
150. Tantravahi J, Womer KL, **Kaplan B.** Why hasn't eliminating acute rejection improved graft survival? *Annu Rev Med.* 2007;58:369-85. doi: 10.1146/annurev.med.58.061705.145143.
151. Tang IY, Meier-Kriesche HU, **Kaplan B.** Immunosuppressive strategies to improve outcomes of kidney transplantation. *Semin Nephrol.* 2007 Jul;27(4):377-92. doi: 10.1016/j.semnephrol.2007.03.002.
152. Thielke J, **Kaplan B,** Benedetti E. The role of ABO-incompatible living donors in kidney transplantation: state of the art. *Semin Nephrol.* 2007 Jul;27(4): 408-413. doi: 10.1016/j.semneohrol.2007.03.003.
153. Rodriguez JR, Reed AI, Nelson DR, Jamieson I, **Kaplan B,** Howard RJ. The financial burden of transplantation: a single-center survey of liver and kidney transplant recipients. *Transplantation.* 2007 Aug 15;84(3):295-300. doi: 10.1097/01.tp.0000269797.41202.79
154. Womer KL, Guerra G, Dibadj K, Huang Y, Kazory A, **Kaplan B.** Srinivas TR. Immunosuppression reduction for BK virus nephropathy: a case for caution. *Transpl Infect Dis.* 9(3): 244-248, 2007 Sep.

155. Bromberg J, **Kaplan B**, Halloran P, Robertson RP. The islet transplant experiment: time for a reassessment. *Am J Transplant.* 7(10): 2217-2218, 2007 Oct.
156. West-Thielke P, **Kaplan B**. Therapeutic monitoring of mycophenolic acid: is there clinical utility? *Am J Transplant.* 7(11): 2441-2442, 2007 Nov.
157. Sis B, **Kaplan B** and Halloran PF. Histologic findings from positive crossmatch or ABO-incompatible renal allografts: accommodation or chronic allograft injury? *Am J Transplant.* 7(12): 2712-2722, 2007 Dec.
158. Mueller T, Einecke G, Reeve J, Sis B, Mengel M, Wishart D, **Kaplan B** Halloran P. Microarray analysis of rejection in human kidney transplants using pathogenesis-based transcript sets. *Am J Transplant.* 7(12): 2712-2722, 2007 Dec.
159. West-Thielke P, **Kaplan B**. Drug concentrations as a biomarker in Transplant. *Therapeutic Reviews* 2007.
160. West-Thielke P, Herren H, Thielke J, Oberholzer J, Sankary H, Raofi V, Benedetti E, **Kaplan B**. Results of positive cross-match transplantation in African American renal transplant recipients. *Am J Transplant.* 8(2): 348-354, 2008 Feb.
161. Meier Kriesche HU, Magee J, **Kaplan B**. Trials and tribulations of steroid withdrawal after kidney transplantation. *Am J Transplant.* 8(2): 265-266, 2008 Feb.
162. Simon G, Parker M, Ramiya V, Wasserfall C, Huang Y, bresson D, Schwartz RF, Campbell-Thompson M, Tenace L, Brusko T, Xhu S, Scaria A, Lukason M, Eisenbeis S, Williams J, Clare-Salzler M, Schatz D, **Kaplan B**, Von Herrath M, Womer KL, and Atkinson MA. Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time dependent induction of immunoregulation. *Diabetes* 57(2): 405-415, 2008 Feb.
163. Simon G, Parker M, Ramiya V, Wasserfall C, Huang Y, Bresson D, Schwartz RF, Campbell-Thompson M, Tenace L, Brusko T, Xue S, Scaria A, Lukason M, Eisenbeis S, Williams J, Clare-Salzler M, Schatz D, **Kaplan B**, Von Herrath M, Womer K, Atkinson MA. Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction. *Diabetes.* 57(2): 405-414, 2008 Feb.
164. Simon G, Parker M, Ramiya V, Wasserfall C, Huang Y, Bresson D, Schwartz RF, Campbell-Thompson M, Tenace L, Brusko T, Xue S, Scaria A, Lukason M, Eisenbeis S, Williams J, Clare-Salzler M, Schatz D, **Kaplan B**, Von Herrath M, Womer K, Atkinson MA. Murine antithymocyte globulin therapy alters disease progression in NOD mice by a time-dependent induction of immunoregulation. *Diabetes.* 2008 Feb;57(2):405-14. doi: 10-2337/db06-1384.
165. Rodriguez JR, Cornell DL, **Kaplan B**, Howard RJ. Patients' willingness to talk to others about living kidney donation. *Prog Transplant.* 2008 Mar;18(1):25-31. PMID: 18429579
166. Kahn LH, **Kaplan B**, Monath TP, Stelle JH. Teaching "one medicine, one health." *Am J Med.* 2008 Mar;121(3):169-70. doi: 10.1016/j.amjmed.2007.09.023
167. **Kaplan B**, West P, Neeley H, Martello J, Gangemi A, Sankary H, Benedetti E, Oberholzer JO. Use of low dose tacrolimus, mycophenolate mofetil and maintenance IL-2 receptor blockade in an islet transplant recipient. *Clin Transpl.* 22(2): 250-253, 2008 Mar-Apr.
168. Rodrigue JR, Cornel D, **Kaplan B**, Howard RJ. A randomized trial of a home-based educational approach to increase live donor kidney transplantation: effects in blacks and whites. *Am J Kidney Dis.* 2008 Apr 15;51(4): 663-70. doi: 10.1053/j.ajkd.2007.11.027.
169. West P, Schmiedeskamp M, Neeley H, Oberholzer J, Benedetti E, **Kaplan B**. Use of high-dose ganciclovir for a resistant cytomegalovirus infection due to UL97 mutation. *Transpl Infect Dis.* 10(2): 129-132, 2008 Apr.
170. Miller G, **Kaplan B**. Prophylaxis versus preemptive protocols for CMV: do they impact graft survival? *Am J*

Transplant. 8(5): 913-14, 2008 May.

171. Rodrigue JR, Guenther R, **Kaplan B**, Mandelbrot DA, Pavlakis M, Howard RJ. Measuring the expectations of kidney donors: initial psychometric properties of the Living Donation Expectancies Questionnaire. *Transplantation.* 2008 May 15;85(9):1230-4. doi: 10.1097/TP.0b013e31816c5ab0.
172. Gangemi A, Salehi P, Hatipoglu B, Martellot J, Barbaro B, Kuechle JB, Qi M, Wang Y, Pallan P, Owens C, Bui J, West D, **Kaplan B**, Benedetti E, Oberholzer J. Islet transplantation for brittle type 1 diabetes: the UIC protocol. *Am J Transplant.* 8(6): 1250-1261, 2008 Jun.
173. Halloran P, Bromberg J, **Kaplan B**, Vincenti F. Tolerance versus immunosuppression: a perspective. *Am J Transplant.* 8(7):1365-1366, 2008 Jul.
174. Campara M, West-Thielke P, Thielke JP, Ommert T, Oberholzer J, Benedetti E, **Kaplan B**. ABO incompatible renal transplantation in an HIV-seropositive patient. *Transplantation.* 2008 Jul 15;86(1):176-178. doi: 10.1097/TP.0b013e31817cf403.
175. Schold JD, **Kaplan B**. Design and analysis of clinical trials in transplantation: principles and pitfalls. *Am J Transplant.* 8(9): 1779-1785, 2008 Sep.
176. **Kaplan B**, Schold JD. The practical utility of an economic analysis of calcineurin withdrawal following renal transplantation. *J Am Soc Nephrol.* 2008 Sep;19(9):1627-1628. doi: 10.1681/ASN.2008070723.
177. Womer KL, Patton PR, **Kaplan B**. Aggressive post-transplant monitoring of more importance to successful outcome following re-transplantation for BK virus nephropathy than absence of pretransplant viremia. *Transpl Int.* 2008 Nov;21(11): 1103-1104. doi: 10.1111/j.1432-2277.2008.00721.x.
178. Howard RJ, **Kaplan B**. The time is now: formation of true transplant centers. *Am J Transplant.* 2008 Nov;8(11): 2225-2229. doi: 10.1111/j.1600-6143.2008.02388.x.
179. **Kaplan B**, West-Thielke P, Herren H, Gill J, Knoll GA, Oberholzer J, Sankary H, Benedetti E. Reported isolated pancreas rejection is associated with poor kidney outcomes in recipients of a simultaneous pancreas kidney transplant. *Transplantation.* 2008 Nov 15;86(9): 1229-1233. doi: 10.1097/TP.0b013e318188ad11.
180. Mengel M, Reeve J, Bunnag S, Einecke G, Sis B, Mueller T, **Kaplan B**, Halloran PF. Molecular correlates of scarring in kidney transplants: the emergency of mast cell transcripts. *Am J Transplant.* 9(1): 169-178, 2009 Jan.
181. Nanovic L, **Kaplan B**. The advantage of live-donor kidney transplantation in older recipients. *Nat Clin Pract Nephrol.* 2009 Jan;5(1): 18-19. doi: 10.1038/ncpneph0987.
182. Thielke JJ, West-Thielke PM, Herren HL, Bareato U, Ommert T, Vidanovic V, Campbell-Lee SA, Tzvetanov IG, Sankary HN, **Kaplan B**, Benedetti E, Oberholzer J. Living donor kidney transplantation across positive crossmatch: the University of Illinois at Chicago experience. *Transplantation.* 2009 Jan 27;87(2): 268-273. doi: 10.1097/TP.0b013e3181919a16.
183. **Kaplan B**, Schold J. Transplantation: neural networks for predicting graft survival. *Nat Rev Nephrol.* 2009 Apr;5(4):190-192. doi: 10.1038/nrneph.2009.24
184. Gangemi A, Tzvetanov IG, Beatty E, Oberholzer J, Testa G, Sankary HN, **Kaplan B**, Benedetti E. Lessons learned in pediatric small bowel and liver transplantation from living-related donors. *Transplantation.* 2009 Apr 15;87(7): 1027-1030. doi: 10.1097/TP.0b013e31819cc3bf.
185. Bunnag S, Einecke G, Reeve J, Jhangri GS, Mueller TF, Sis B, Hidalgo LG, Mengel M, Kayser D, **Kaplan B**, Halloran PF. Molecular correlates of renal function in kidney transplant biopsies. *J Am Soc Nephrol.* 2009 May;20(5):1149-1160. doi: 10.1681/ASN.2008080863.

186. Nanovic L **Kaplan B**. Reliability of Medicare claim forms for outcome studies in kidney transplant recipients: epidemiology in clinical outcome trials. *Clin J Am Soc Nephrol*. 2009 Jul;4(7): 1156-1158. doi: 10.2215/CJN.03300509.
187. Gaston, RS, Murphy M, **Kaplan B**, Shah T, Mulgaonkar S, Meier H, Bloom R, Cibrik D, Shaw L, Angelis, M. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Optcept trial. *Am J Transplant*. 9(7): 1607-1619, 2009 Jul.
188. Reeve J, Einecke G, Mengel M, Sis B, Kayser N, **Kaplan B**, Halloran PF. Diagnosing rejection in renal transplants: a comparison of molecular- and histopathology-based approaches. *Am J Transplant*. (9)8: 1802-1810, 2009 Aug.
189. Schold JD, **Kaplan B**. AZA/tacrolimus is associated with similar outcomes as MMF/tacrolimus among renal transplant recipients. *Am J Transplant*. 9(9): 2067-2074, 2009 Sep.
190. Sis B, Jhangri GS, Bunnag S, Allanach K, **Kaplan B**, Halloran PF. Endothelial gene expression in kidney transplants with alloantibody indicates antibody-mediated damage despite lack of C4d staining. *Am J Transplant*. 2009 Oct;9(10):2312-2323. doi: 10.1111/j.1600-6143.2009.02761.x.
191. **Kaplan B**: Literature Review on van Gelder T et al (2008 Transplantation) Comparing Mycophenolate Mofetil Regimens for de Novo Renal Transplant Recipients: The Fixed-Dose Concentration-Controlled Trial. *Transplantation Index and Reviews* 2009(2):1.
192. Womer KL, Huang Y, Herren H, Dibadj K, Peng R, Murawski M, Shraybman R, Patton P, Clare-Salzler MJ, **Kaplan B**. Dendritic Cell Deficiency Associated with the Development of BK Viremia and Nephropathy in Renal Transplant Recipients. *Transplantation*. 2010 Jan 15;89(1): 115-123. doi: 10.1097/TP.0bo13e3181bc6096.
193. Sis B, Einecke G, Chang J, Hidalgo LG, Mengel M, **Kaplan B**, Halloran P. Cluster analysis of lesions in nonselected kidney transplant biopsies: microcirculation changes, tubulointerstitial inflammation and scarring. *Am J Transplant*. 10(7): 421-430, 2010 Feb.
194. **Kaplan B**, Gaston RS, Meier-Kriesche HU, Bloom RD, Shaw LM. Mycophenolic acid exposure in high- and low-weight renal transplant patients after dosing with mycophenolate mofetil in the Optcept trial. *Ther Drug Monit*. 2010 Apr;32(2):224-227. doi: 10.1097/TP.0bo13e3181d18baa.
195. Famulski K, Einecke G, Sis B, Mengel M, Hidalgo L, **Kaplan B** Halloran P. Defining the canonical form of T-cell-mediated rejection in human kidney transplants. *Am J Transplant*. 10(9): 810-820, 2010 Apr.
196. **Kaplan B**, Jie T, Diana R, Renz J, Whinery A, Stubbs N, Bracamonte E, Spier C, Schubart P, Rilo H, Gruessner R. Histopathology and Immunophenotype of the spleen during acute antibody-mediated rejection. *Am J Transplant* 10(5): 1316-1320, 2010 Apr.
197. Schold JD, **Kaplan B**. The elephant in the room: failings of current clinical endpoints in kidney transplantation. *Am J Transplant* 10(5):1163-1166, 2010 May.
198. Einecke G, Reeve J, Sis B, Mengel M, Hidalgo L, Famulski KS, Matas A, Kasiske B, **Kaplan B**, Halloran PF. A molecular classifier for predicting future graft loss in late kidney transplant biopsies. *J Clin Investigation*. 2010 Jun;120(6):1862-72. doi: 10.1172/JCI41789.
199. Schold J, Sehgal A, Srinivas T, Poggio E, Navaneethan S, **Kaplan, B**. Marked variation of the association of ESRD duration before and after wait listing on kidney transplant outcomes. *Am J Transplant* 10(9): 2008-2016, 2010 Sept.
200. **Kaplan, B**. Kidney Transplantation. Guest Editor, Virtual Issue. *Am J Transplant*, Sept 2010.

201. Srinivas TR, **Kaplan B**, Meier-Kriesche HU. The noninferiority trial: don't don't do it. *Am J Transplant* 10(12):571-2573, 2010 Dec.
202. Segev D, Massie A, Schold J, **Kaplan B**. If you are not fit, you must not quit: observational studies and weighing the evidence. *Am J Transplant* 11:1-2, 2011 Feb.
203. Stevens RB, Lane JT, Boerner BP, Miles CD, Rigley TH, Sandoz JP, Nielsen KJ, Skorupa JY, Skorupa AJ, **Kaplan B**, Wrenshall LE. Single-dose rATG induction at renal transplantation: superior renal function and glucoregulation with less hypomagnesemia. *Clin Transplantation*. 2012 Jan-Feb;26(1):123-32. doi: 10.1111/j.1399-0012.2011.01425x.
204. Sellares J, de Freitas DG, Mengel M, Sis B, Hidalgo LG, Matas AJ, **Kaplan B**, Halloran PF. Inflammation lesions in kidney transplant biopsies: association with survival is due to the underlying diseases. *Am J Transplant* 11(3):489-499, 2011 Mar.
205. Askar M, Schold J, Egtesad B, Flechner SM, **Kaplan B**, Klingman L, Zein NN, Fung J, Srinivas TR. Combined Liver-Kidney Transplants: Allosensitization and Recipient Outcomes. *Transplantation*. 2011 Jun 15;91(11):1286-92. doi: 10.1097/TP.0bo13e3182184181.
206. Shapiro, R and **Kaplan B**. Native renal cysts and dialysis duration are risk factors for renal cell in renal transplant recipients. *Am J Transplant* 11(1): 2010.
207. Ekberg H, van Gelder T, **Kaplan B**, Bernasconi C. Relationship of tacrolimus exposure and mycophenolate mofetil does with renal function after renal transplantation. *Transplantation*. 2011 Jul 15;92(1):82-87. doi: 10.1097/TP.0bo13e31821fad06.
208. Meier-Kriesche H-U, **Kaplan B**. The search for CNI free immunosuppression: no free lunch. *Am J Transplantation* 11(7):1355-6, 2011 Jul.
209. Avery R, **Kaplan B**. Immunosuppressive agents and CMV risk in the VICTOR study. *Am J Transplant* 10(8):1727-1728, 2010 Aug.
210. Yost SE, Srinivas T, **Kaplan B**. Ethical considerations regarding disparities pertaining to kidney transplant patients. *Clin Pharmacol Ther* 90(2):212-4, 2011 Aug.
211. Yost SE, Byrne R, **Kaplan B**. Transplantation: mTOR inhibition in kidney transplant recipients. *Nat Rev Nephrol*. 2011 Aug 30;7(10):553-5. doi: 10.1038/nrneph.2011.125.
212. Yost S, Byrne R, **Kaplan B**. mTOR inhibition in kidney transplant recipients. News & Views in *Nature Reviews Nephrology* 7(10):553-555, 2011 Aug.
213. Chisholm-Burns MA, Erickson SR, Spivey CA, Gruesser R, **Kaplan B**. Concurrent validity of kidney transplant questionnaire in US renal transplant recipients. *Patient Prefer Adherence*. 2011 Oct 13;(5):517-22. doi: 10.2147/PPA.S24216.
214. Srinivas TR and **Kaplan B**. Transplantation in 2011: New agents, new ideas and new hope. *Nat Rev Nephrol*. 2011 Dec 20;8(2):74-5. doi: 10.1038/nrneph.2011.215.
215. Breidenbach W, Tolgaturker, Gorantlav, Kahand, **Kaplan B**. Intimal Hyperplasia in hand transplant and composite tissue allotransplantation. Submitted *Transplantation*, 2012
216. Blume OR, Yost SE, **Kaplan B**. Antibody-mediated rejection: pathogenesis, prevention, treatment, and outcomes. *J Transplantation*. 2012 Mar 24;2012:201754. doi: 10.1155/2012/201754.

217. Chisholm-Burns MA, Erickson SR, Spivey CA, **Kaplan B**. Health-related quality of life and employment among renal transplant recipients. *Clin Transplant*. 2012 May-Jun;26(3):411-417. doi: 10.1111/j.1399-0012.2011.01541.x.
218. Tzventanov I, Spaggiari M, Oberholzer J, Setty S, Stephenson A, Thielke J, West-Thielke, Jeon H, Danielson KK, **Kaplan B**, Benedetti E. Cell population in spleens during antibody mediated rejection: pathological and clinical findings. *Transplantation*. 2012 Aug 15;94(3):255-62. doi: 10.1097/TP/obo13e3182562881.
219. **Kaplan B**. et al. Waitlist and Transplant Outcomes Among Kidney Candidates with Inactive Status Due to Being Temporarily Too Sick. *Transplantation* in press, 2012 Oct.
220. Yost SE, **Kaplan B**. Comparing Kidney Transplant Outcomes; Caveats and Lessons. *Neph Dial Transplant*. 2013 Jan;28(1):9-11. doi: 10.1092.ndt/gfs374.
221. Bouamar R, Shukar N, Hesselink D, Weimar W, Ekberg H, **Kaplan, B**, Bernasconi C. van Gelder T. Tacrolimus predose concentrations do not predict the risk of acute rejection after renal transplantation: a pooled analysis from three randomized-controlled clinical trials. *Am J Transplant* 13(5):1253-61, 2013 Mar.
222. Lian F and **Kaplan B** et al. TH₁₇ is necessary for angiotensin II induced vasoconstriction. Submitted to *J Clin Investigation*, Nov 2012.
223. **Kaplan B** and Sweeney JF. Assessing 30-day hospital readmission after renal transplantation: a complex Task. *Am J Transplant* 12(12):3171-2, 2012 Dec.
224. Sun Q, Hall EC, Huang Y, Chen P, Dibadj K, Murawski M, Shraybam R, Van Kirk K, Tang V, Peng R, Patton PR, Clare-Salzler MJ, **Kaplan B**, Segev DL, Womer KL. Pre-Transplant Myeloid Dendritic Cell Deficiency Associated with Cytomegalovirus Infection and Death After Kidney Transplantation. *Transpl Infect Dis* 14(6):618-25, 2012 Dec.
225. Tawinwung S, Majeed B, Eberson L, **Kaplan B**, Larson D. The Effect of Angiotensin II on Renal Function is Modulated by CD4 Lymphocytes. *J Am Soc Neph*, submitted Feb 2013.
226. Danielson KK, Hatipoglu B, Kinzer K, **Kaplan B**, Martellotto J, Qi M, Mele A, Benedetti E, Oberholzer J. Reduction in Carotid Intima-Media Thickness After Pancreatic Islet Transplantation in Patients with Type I Diabetes. *Diabetes Care* 36(2):450-6, 2013 Feb.
227. Turgeon N and **Kaplan B**. Risky Business: Models of Risk in Transplant. *Am J Transplant* 13(5):1121-2, 2013 May.
228. Bouamar R, Shuker NM, Hesselink DA, Weimar W, Ekberg H, Bernasconi C, **Kaplan B**, Bernasconi C, Van Gelder T. Tacrolimus Predose Concentrations do Not Predict the Risk of Acute Rejection After Renal Transplantation: A Pooled Analysis from Three Randomized-Controlled Clinical Trials. *Am J Transplant* 13(5):1253-61, 2013 May.
229. Gaber AO, Alloway RR, Bodziak K, **Kaplan B**, Conversion from twice-daily tacrolimus capsules to once-daily extended-release tacrolimus (LCPT): a phase II trial of stable renal transplant recipients. *Transplantation* 2013 Jul;96(2):191-7. doi: 10.1097/TP.0b013e3182962cc1.
230. Boyer T, **Kaplan B**. Renal failure and liver transplantation. *Clin Liver Dis (Hoboken)*. 2013 Jun 21;2(3):106-108. doi: 10.1002/cld.170.eCollection 2013 Jun.
231. Van Gelder T, **Kaplan B**, Ekberg H. Tacrolimus exposure does not impact T-cell mediated rejection. *Transplantation* (in press) 2013.
232. Koppula S, Yost S, Sussman A, Bracamonte ER, **Kaplan B**. Successful conversion to belatacept after thrombotic microangiopathy in kidney transplant patients. *Clin Transplant* 27(4):591-7, 2013 Jul.

233. Rana A, Gruessner R, **Kaplan B**, Gruessner A, Habib S, Porubsky M, Jie T, Rilo H. The survival outcomes following liver transplantation (SOFT) score: validation with contemporaneous data and stratification of high risk cohorts. *Clin Transplant*. 2013 Jul-Aug;27(4):627-32. doi: 10.1111/ctr.12181.
234. Rana A, Gruesser R, **Kaplan B**, Gruessner A, Habib S, Porubsky M, Jie T, Rilo H. A critical analysis of early death after adult liver transplants. *Clin Transplant*. 2013 Jul-Aug;27(4):E448-53. doi: 10.1111/ctr.12186.
235. Rana A, Jie T, Porubsky M, Habib S, Rilo H, **Kaplan B**, Gruessner A, Gruessner R. The survival outcomes following liver transplantation (SOFT) score: validation with contemporaneous data and stratification of high-risk cohorts. *Clin Transplant* 27(4):627-32, 2013 Jul-Aug.
236. Koppula S, Yost SE, Sussman A, Bracamonte ER, **Kaplan B**. Successful conversion to belatacept after thrombotic microangiopathy in kidney transplant patients. *Clin Transplant*. 2013 Jul-Aug;27(4):591-7. doi: 10.1111/ctr.12170
237. Harton GL, Munné S, Surrey M, Grifo J, **Kaplan B**, McCulloh DH, Griffin DK, Wells D. Diminished effect of maternal age on implantation after preimplantation genetic diagnosis with array comparative genomic hybridization. *Fertil Steril*, 10.1016/j.fertnstert.2013.07.2002 EPub, 2013 Sept.
238. Srinivas TR, **Kaplan B**. Urinary biomarkers and kidney transplant rejection: fine-tuning the radar. *Am J Transplantation* 13(10):2519-21, 2013 Oct.
239. Gillespie M, Yost S, Meister E, **Kaplan B**. A cautionary tale of BK virus. *Transpl Int*. 2013 Nov;26(11):e99. doi: 10.1111/tri.12161
240. Lo D, **Kaplan B**, Kirk AD. Biomarkers for Kidney Transplant Rejection. *Nat Rev Nephrol*. 2014 Apr;10(4):215-25. doi: 10.1038/nrneph.2013.281
241. Leeaphorn N, Sampaio MS, Natal N, Mehrnia A, Kamgar M, Huang E, Kalantar-Zadeh K, **Kaplan B**, Bunnapradist S. Renal Transplant Outcomes in Waitlist Candidates with a Previous Inactive Status Due to Being Temporarily Too Sick. *Clin Transpl*. 2014:117-24. PMID: 26281135
242. Yost SE, Echeverria A, Jie T, **Kaplan B**. Panresistant Cytomegalovirus in a kidney transplant recipient. *Pharmacotherapy*. 2014 Jan;34(1):e1-3. doi: 10.1002/phar.1373.
243. Boyer TD, **Kaplan B**. Insuficiencia renal y trasplante hepático. *Clin Liver Dis (Hoboken)*. 2014 Jan 13;2(Suppl 5):95-97. doi: 10.1002/cld.283.eCollection 2013 Nov.
244. **Kaplan B**. Report cards and quality: do center report cards predict quality or simply predict the next report card? *Am J Transplant* 14(1):238, 2014 Jan.
245. Rana A, Petrowsky H, **Kaplan B**, Jie T, Porubsky M, Habib S, Rilo H, Gruessner AC, Gruessner RW. Early liver retransplantation in adults. *Transpl Int*. 2014 Feb;27(2):141-51. doi: 10.1111/tri.12201.
246. **Kaplan B**, Qazi Y, Wellen JR. Strategies for the management of adverse events associated with mTOR inhibitors. *Transplant Rev (Orlando)*. 2014 Jul;28(3):126-33. doi: 10.1016/j.ttre.2014.03.002.
247. Shihab F, Christians U, Smith L, Wellen JR, **Kaplan B**. Focus on mTOR inhibitors and tacrolimus in renal transplantation: pharmacokinetics, exposure-response relationships, and clinical outcomes. *Transpl Immunol*. 2014 Jun;31(1):22-32. doi: 10.1016/j.trim.2014.05.002.
248. Gupta A, **Kaplan B**. Transplantation: CNIs to mTOR inhibitors-effects on allosensitization? *Nat Rev Nephrol*. 2014 Aug;10(8):425-6. doi: 10.1038/nrneph.2014.94.
249. Chong AS, **Kaplan B**. New Kid on the Pretransplant Block: IgG Recognizing Apoptotic Cells. *Am J Transplantation* 14(7):1477-1478, July 2014.

250. Bakhtar O, Thajudeen B, Braunhut BL, Yost SE, Bracamonte ER, Sussman AN, **Kaplan B**. A case of thrombotic microangiopathy associated with antiphospholipid antibody syndrome successfully treated with eculizumab. *Transplantation*. 2014 Aug 15;98(3):e17-8. doi: 10.1097/TP.0000000000000267.
251. Gupta, A., Chen, G., & **Kaplan, B**. (2014). KDPI and Donor Selection. *American Journal of Transplantation*, 14(11), 2444–2445. doi: 10.1111/ajt.12930
252. Gupta A, Kumer S, **Kaplan B**. Novel immunosuppressive strategies for composite tissue allografts. *Curr Opin Organ Transplant*. 2014 Dec;19(6):552-7. doi: 10.1097/MOT.0000000000000135.
253. Hogan JL, Rosenthal SJ, Yarlagadda SG, Jones JA, Schmitt TM, Kumer SC, **Kaplan B**, Deas SL, Mawabi AM. Late-onset renal vein thrombosis: A case report and review of the literature. *Int J Surg Case Rep*. 2015;6C:73-6. doi: 10.1016/j.ijscr.2014.09.027.
254. Srinivas TR, Ho B, Kang J, **Kaplan B**. (2015). Post Hoc Analyses: after the facts. *Transplantation*. 2015 Jan; 99(1):17–20. doi: 10.1097/tp.0000000000000581
255. Mehrotra S, Ladner D, Gilroy R, Klintmalm GB, and **Kaplan B**, Modeling Liver Allocation System: Principles for Robust Design Before Restructuring. *Transplantation* 2015;99:278-81.
256. Abecassis, M., **Kaplan, B**. Transplantation: Biomarkers in transplantation—the devil is in the detail. *Nat Rev Nephrol*. 2015 Apr;11(4):204-5. doi:10.1038/nrneph.2015.2
257. Mehrotra S, Kilambi V, Gilroy R, Ladner DP, Klintmalm GB, **Kaplan B**. Modeling the allocation system: principles for robust design before restructuring. *Transplantation*. 2015 Feb;99(2):278-81. doi: 10.1097/TP.0000000000000656.
258. Reeve, J, Halloran PF, and **Kaplan B.**, Common Errors in the Implementation and interpretation of microarray studies. *Transplantation* 2015 Mar;99(3):470-5. doi: 10.1097/TP.0000000000000372.
259. Rana A, **Kaplan B**, Riaz IB, Porubsky M, Habib S, Rilo H, Gruessner AC, Gruessner RW. Geographic inequities in liver allograft supply and demand: does it affect patient outcomes? *Transplantation*. 2015 Mar;99(3):515-20. doi: 10.1097/TP.0000000000000754.
260. Rana A, Gruessner A, Agopian VG, Khalpey Z, Riaz IB, **Kaplan B**, Halazun KJ, Busuttil RW, Gruessner RW. Survival benefit of solid-organ transplant in the United States. *JAMA Surg*. 2015 Mar 1;150(3):252-9. doi: 10.1001/jamasurg.2014.2038.
261. Loucks J, Yost S, **Kaplan B**. An introduction to basic pharmacokinetics. *Transplantation*. 2015 May;99(5):903-7. doi: 10.1097/TP.0000000000000754.
262. Rodrigue JR, Schold JD, Morrissey P, Whiting J, Vella J, Kayler LK, Katz D, Jones J, **Kaplan B**, Fleishman A, Pavlakakis M, Mandelbrot DA; KDOC Study Group: Predonation Direct and Indirect Costs Incurred by Adults Who Donated a Kidney: Findings From the KDOC Study. *Am J Transplant*. 2015 May 5
263. Gupta A, Ho B, Ladner DP, Kang J, Skaro A, **Kaplan B**. Program-specific Reports: A Guide to the Debate. *Transplantation*. 2015 Jun;99(6):1109-12. doi: 10.1097/TP.0000000000000799.
264. Skaro AI, Hazen G, Ladner D, **Kaplan B**. Organ Transplantation: An Introduction to Game Theory. *Transplantation*. 2015 Jul;99(7):1316-20. doi: 10.1097/TP.0000000000000817.
265. Viswesh V, Yost SE, **Kaplan B**. The prevalence and implications of BK virus replication in non-renal solid organ transplant recipients: A systematic review. *Transplant Rev (Orlando)*. 2015 Jul;29(3):175-180. doi: 10.1016/j.trre.2015.02.004.

266. Tambur AR, Haarberg KM, Friedewald JJ, Leventhal JR, Cusick MF, Jaramillo A, Abecassis MM, **Kaplan B**. Unintended Consequences of the New National Kidney Allocation Policy in the United States *Am J Transplant*. 2015 July
267. Mehrotra S, Kilambi V, Gilroy R, Ladner DP, Klintmalm GB, **Kaplan B**. The Author's Reply. *Transplantation*. 2015 Sep;99(9):e160-1. doi: 10.1097/TP.0000000000000833
268. Tambur AR, Haarberg KM, Friedewald JJ, Leventhal JR, Cusick MF, Jaramillo A, Abecassis MM, **Kaplan B**. Unintended Consequences of the New National Kidney Allocation Policy in the United States. *Am J Transplant*. 2015 Sep;15(9):2465-9.
269. Schnier KE, Turgeon NA, **Kaplan B**. A Primer of Neoclassical (Traditional) and Behavioral Economic Principles for Organ Transplantation: Part 1. *Transplantation*. 2015 Oct; 99(10): 2024-8. doi: 10.1097/TP.0000000000000904.
270. **Kaplan, B**. Decade in review-renal transplantation: A spectrum of advances in renal transplantation. *Nat. Rev. Nephrol*. 2015. Nov; 11(11): 639-41. doi: 10/1038/nrneph.2015.159
271. Ilahe A, Budhiraja P, **Kaplan B**. Polyclonal and monoclonal antibodies in renal transplant: an update. *Curr Opin Nephrol Hypertens*. 2015 Nov; 14(6):563-9.
272. Schnier KE, Turgeon N, **Kaplan B**. A Primer of Neoclassical (Traditional) and Behavioral Economic Principles for Organ Transplantation: Part 1. *Transplantation*. 2015 Nov; 99(11): 2247-51. doi: 10.1097/TP.0000000000000904
273. Singh SK, **Kaplan B**, Joeseeph Kim S. Multivariable Regression Models in Clinical Transplant Research: Principles and Pitfalls. *Transplantation*. 2015 Dec; 99(12):2451-7. doi: 10.1097/TP.0000000000000996.
274. McCullough JM, **Kaplan B**. A Random Walk Through Large Data: Caveats Regarding the Potential for False Inference. *Transplantation*. 2016 Jan; 100: (1)18-22. doi: 10.1097/TP.0000000000001046
275. Neapolitan R, Jiang X, Ladner DR, **Kaplan B**. A Primer on Bayesian Decision Analysis With an Application to a Kidney Transplant Decision. *Transplantation*. 2016 Mar;100(3):489-96. doi: 10.1097/TP.0000000000001145.
276. Breidenbach, W. C., Meister, E. A., Becker, G. W., Turker, T., Gorantla, V. S., Hassan, K., & **Kaplan, B**. (2016). A Statistical Comparative Assessment of Face and Hand Transplantation Outcomes to Determine Whether Either Meets the Standard of Care Threshold. *Plastic and Reconstructive Surgery*, 137(1), 214e–222e. doi: 10.1097/prs.0000000000001893
277. Schold, JD, & **Kaplan, B**. Living Kidney Donor Profile Index: Utility and Limitations. *Am J Transplant* 2016; 16: 1951– 1952. Doi: 10.1111/ajt.13727.
278. Heilman RL, Mathur A, Smith ML, **Kaplan B**, Reddy KS. Increasing the Use of Kidneys From Unconventional and High-Risk Deceased Donors. *Am J Transplant*. 2016 Nov; 16 (11):3086-3092 Epub 2016 June 14
279. Chakkera HA, Schold JD, **Kaplan B**. P Value: Significance Is Not All Black and White. *Transplantation* 2016 Aug; 100 (8):1607-9. doi: 10.1097
280. Coletta DK, Campbell LE, Weil J, **Kaplan B**, Clarkson M, Finlayson J, Mandarino LJ, Chakkera HA. Changes in Pre- and Post-Exercise Gene Expression among Patients with Chronic Kidney Disease and Kidney Transplant Recipients. *PLoS One*. 2016; 11 (8):e0160327 Epub 2016 Aug 12. doi: 10.1371/journal.pone.0160327. eCollection 2016
281. Moss A, **Kaplan B**. Transplantation: Utilizing the transcriptome to predict allograft fibrosis. *Nat Rev Nephrol*. 2016 Nov; 12 (11):652-653 Epub 2016 Sept 19. doi: 10.1038/nrneph.2016.134

282. Farnon EC, Kokko KE, Budge PJ, Mbaeyi C, Lutterloh EC, Qvarnstrom Y, da Silva AJ, Shieh WJ, Roy SL, Paddock CD, Sriram R, Zaki SR, Visvensvara GS, Kuehnert MJ, Balamuthia Transplant Investigation Teams, Weiss J, Komatsu K, Manch R, Ramos A, Echeverria L, moore A, Zakowski P, kittleson M, Kobashigawa J, Yoder J, Beach M, Mahle W, Kanter K, Geraghty PJ, Navarro E, Hahn C, Fujita S, Stinson J, Trachtenberg J, Byers P, Cheung M, Jie T, **Kaplan B**, Gruessner R, Bracamonte E, Viscusi C, Gonzalez-Peralta R, Lawrence R, Fratkin J, Butt F. Transmission of Balamuthia mandrillaris by Organ Transplantation. *Clin Infect Dis*. 2016 Oct 1;63(7):878-888. doi: 10.1093/cid/ciw422.
283. Heilman RL, Smith ML, Smith BH, Qaqish I, Khamash H, Singer AL, **Kaplan B**, Reddy KS. Progression of Interstitial Fibrosis during the First Year after Deceased Donor Kidney Transplantation among Patients with and without Delayed Graft Function. *Clin J Am Soc Nephrol*. 2016 Dec 7; 11 (12):2225-2232 Epub 2016 Oct 24
284. Stroud C, **Kaplan B**, Logan JE, Gray GC. One Health training, research and outreach in North America. *Infect Ecol Epidemiol*. 2016 Nov 29;6:33680. doi: 10.3402/iee.v6.33680.
285. Chakkera HA, Kudva Y, **Kaplan B**. Calcineurin Inhibitors: Pharmacologic Mechanisms Impacting Both Insulin Resistance and Insulin Secretion Leading to Glucose Dysregulation and Diabetes Mellitus. *Clin Pharmacol Ther*. 2017 Jan; 101 (1):114-120 Epub 2016 Nov 21
286. Abecassis M, **Kaplan B**. Caveat emptor: the devil is still in the detail. *Nat Rev Nephrol*. 2017 Jan; 13 (1):60 Epub 2016 Nov 14. doi: 10.1038/nrneph.2016.161.PMID: 2784041
287. King, RW & Kaplan, B. Discontinuing Mycophenolate With Respect to Pregnancy and the Interpretation of Voluntary Registry Results. *Am J Transplant* 2017; 17: 583– 584. doi: 10.1111/ajt.14114
288. King RW, Baca MJ, Armenti VT, **Kaplan B**. Pregnancy Outcomes Related to Mycophenolate Exposure in Female Kidney Transplant Recipients. *Am J Transplant*. 2017 Jan; 17 (1):151-160 Epub 2016 July 15. doi: 10.1111/ajt.13928.
289. Kurian SM, Whisenant T, Mas V, Heilman R, Abecassis M, Salomon DR, Moss A, **Kaplan B**. Biomarker Guidelines for High-Dimensional Genomic Studies in Transplantation: Adding Method to the Madness. *Transplantation*. 2017 Mar; 101 (3):457-463
290. Qazi Y, Shaffer D, **Kaplan B**, Kim DY, Luan FL, Peddi VR, Shihab F, Tomlanovich S, Yilmaz S, McCague K, Patel D, Mulgaonkar S. Efficacy and Safety of Everolimus Plus Low-Dose Tacrolimus Versus Mycophenolate Mofetil Plus Standard-Dose Tacrolimus in De Novo Renal Transplant Recipients: 12-Month Data. *Am J Transplant*. 2017 May; 17 (5):1358-1369 Epub 2017 Jan 04
291. Goss M, Reese J, Kueht M, Vierling JM, Mindikoglu AL, Sussman NL, **Kaplan B**, Wood RP, Rana AA. A Surge in cadaveric liver donors and a national narcotic epidemic: Is there an association? *Liver Transpl* 2017 May; 23 (5):698-700. doi: 10.1002/lt.24761
292. Ilyas M, Colegio OR, **Kaplan B**, Sharma A. Cutaneous Toxicities From Transplantation-Related Medications. *Am J Transplant*. 2017 Nov; 17 (11):2782-2789 Epub 2017 May 30. doi: 10.1111/ajt.14337
293. Heilman RL, Green EP, Reddy KS, Moss A, **Kaplan B**. Potential Impact of Risk and Loss Aversion on the Process of Accepting Kidneys for Transplantation. *Transplantation*. 2017 Jul; 101 (7):1514-1517. doi: 10.1097/TP.0000000000001715. PMID: 28640014
294. Keddis MT, El-Zoghby Z, **Kaplan B**, Meeusen JW, Donato LJ, Cosio FG, Steidley DE. Soluble ST2 Does Not Change Cardiovascular Risk Prediction Compared to Cardiac Troponin T in Kidney Transplant Candidates. *PLoS One*. 2017; 12 (7):e0181123 Epub 2017 July 13. doi: 10.1371/JOURNAL.PONE.0181123
295. Chakkera HA, Sharif A, **Kaplan B**. Negative Cardiovascular Consequences of Small Molecule Immunosuppressants. *Clin Pharmacol Ther*. 2017 Aug; 102: (2)269-276. doi: 10.1002/cpt.738

296. Klintmalm, GB, **Kaplan, B.** The kidney allocation system claims equity: It is time to review utility and fairness. *Am J Transplant.* 2017; 17: 2999– 3000. doi:10.1111/ajt.14457
297. Kransdorf EP, Pando MJ, Gragert L, **Kaplan B.** HLA Population Genetics in Solid Organ Transplantation. *Transplantation.* 2017 Sep; 101 (9):1971-1976
298. Abdelwahab Elhamahmi D, Heilman RL, Smith B, Huskey J, Khamash H, **Kaplan B.** Early Conversion to Belatacept in Kidney Transplant Recipients With Low Glomerular Filtration Rate. *Transplantation.* 2018 Mar; 102 (3):478-483. doi: 10.1097/TP.0000000000001985
299. Chakkera HA, Angadi SS, Heilman RL, **Kaplan B,** Scott RL, Bollempalli H, Cha SS, Khamash HA, Huskey JL, Mour GK, Sukumaran Nair S, Singer AL, Reddy KS, Mathur AK, Moss AA, Hewitt WR Jr, Qaqish I, Behmen S, Keddis MT, Unzek S, Steidley DE. Cardiorespiratory Fitness (Peak Oxygen Uptake): Safe and Effective Measure for Cardiovascular Screening Before Kidney Transplant. *J Am Heart Assoc.* 2018 May 31; 7 (11). doi: 10.1161/JAHA.118.008662
300. Budhiraja, P, **Kaplan, B.** (2018). External Validation of Kidney Donor Risk Index Does Not Mitigate Its Basic Limitations. *Transplantation,* 102(1), 5–6. doi: 10.1097/tp.0000000000001906
301. Rodrigue, JR, Schold, JD, **Kaplan, B.,** Morrissey, P, et al. Mood, body image, fear of kidney failure, life satisfaction, and decisional stability following living kidney donation: Findings from the KDOC study. *Am J Transplant.* 2018; 18: 1397– 1407. doi:10.1111/ajt.14618
302. Johnson, C., & **Kaplan, B.** (2018). Biomarkers and Kidney Transplant: Time for a New Paradigm? *Transplantation,* 102(4), 552–553. doi: 10.1097/tp.0000000000002038
303. Reddy KS, **Kaplan B.** Donor Hypothermia and Organ Transplantation. *Transplantation* 2018 Nov; 102 (11):1789-1790. doi: 10.1097/TP.0000000000002399.
304. Heilman RL, Srinivas TR, **Kaplan B.** On Reporting the Outcomes from Clinical Trials; a Call to Order. *Transplantation.* 2018 Dec;102(12):1996-1967. doi: 10.1097/TP.0000000000002279.
305. Heilman RL, **Kaplan B.** Is Recipient HLA-B51 Status Protective for the Risk of BK Infection After Kidney Transplantation? *Transplantation* 2019 Mar; 103 (3):461-462. doi: 10.1097/TP.0000000000002377
306. Klintmalm, G.B., **Kaplan, B.** and Kirk, A.D. (2019), FDA jeopardizes the lives of lung transplant recipients and in the process severely increases the cost to develop new immunosuppression. *Am J Transplant,* 19: 971-972. doi:10.1111/ajt.15215.
307. Robbins, N. L., Wordsworth, M. J., Parida, B. K., **Kaplan, B.,** Gorantla, V. S., Weitzel, C. E. K., & Breidenbach, W. C. (2019). A Flow Dynamic Rationale for Accelerated Vascularized Composite Allotransplant Rejection. *Plastic and Reconstructive Surgery,* 143(3). doi: 10.1097/prs.0000000000005352.
308. Kilambi V, Bui K, Hazen GB, Friedewald JJ, Ladner DP, **Kaplan B,** Mehrotra S. Evaluation of Accepting Kidneys of Varying Quality for Transplantation or Expedited Placement With Decision Trees. *Transplantation.* 2019 May; 103 (5):980-989. doi: 10.1097/TP.0000000000002585.
309. Robbins, N. L., Wordsworth, M. J., Parida, B. K., **Kaplan, B.,** Gorantla, V. S., Weitzel, E. K., & Breidenbach, W. C. (2019). Is Skin the Most Allogenic Tissue in Vascularized Composite Allotransplantation and a Valid Monitor of the Deeper Tissues? *Plastic and Reconstructive Surgery,* 143(4). doi: 10.1097/prs.0000000000005436
310. Rodrigue, J. R., Fleishman, A., Sokas, C. M., **Kaplan, B.,** Schold, J. D., Morrissey, P., Whiting, J., Mandelbrot, D. A. (2019). Rates of Living Kidney Donor Follow-up: Findings from the KDOC Study. *Transplantation,* 103(7). doi: 10.1097/tp.0000000000002721

311. Rodrigue, JR, Fleishman, A, Schold, JD, **Kaplan, B.**, et al.; the KDOC Study Group. Patterns and Predictors of Fatigue Following Living Donor Nephrectomy: Findings from the KDOC Study. *Am J Transplant*. 2019; 00: 1- 9. doi: [10.1111/ajt.15519](https://doi.org/10.1111/ajt.15519)
312. Mcadams-Demarco, M. A., Rasmussen, S. E. V. P., Chu, N. M., Agoons, D., Parsons, R. F., Alhamad, T., **Kaplan, B.**, Dadhania, D. (2019). Perceptions and Practices Regarding Frailty in Kidney Transplantation: Results of a National Survey. *Transplantation*, 1. doi: 10.1097/tp.0000000000002779
313. Rangaswami, J., Bangalore, S., **Kaplan, B.**, Birdwell, K. A., Wiseman, A. C., Mccullough, P. A., & Dadhania, D. M. (2019). Cardiovascular disease care fragmentation in kidney transplantation: a call for action. *Kidney International*, 96(3), 568–571. doi: 10.1016/j.kint.2019.04.042
314. Sapir-Pichhadze, R., & **Kaplan, B.** (2019). Seeing the Forest for the Trees: Random Forest Models for Predicting Survival in Kidney Transplant Recipients. *Transplantation*, 1. doi: 10.1097/tp.0000000000002923
315. Benedict, J. L., Robbins, N. L., **Kaplan, B.**, & Breidenbach, W. C. (2019). A Call to Accountability: Reporting Outcomes in Vascularized Composite Allotransplantation. *Plastic and Reconstructive Surgery - Global Open*, 7(6). doi: 10.1097/gox.0000000000002266
316. Naesens, M., Friedewald, J., Mas, V., **Kaplan, B.**, & Abecassis, M. M. (2019). A Practical Guide to the Clinical Implementation of Biomarkers for Subclinical Rejection Following Kidney Transplantation. *Transplantation*, 1. doi: 10.1097/tp.0000000000003064
317. Budhiraja, P., **Kaplan, B.**, & Mustafa, R. A. (2020). Handling of Missing Data. *Transplantation*. 2020 Jan;104(1), 24–26. doi: 10.1097/tp.0000000000002865
318. McAdams-DeMarco MA, Van Pilsum Rasmussen SE, Chu NM, Agoons D, Parsons RF, Alhamad T, Johansen KL, Tullius SG, Lynch R, Harhay MN, Rao MK, Berger J, Cooper M, Tan JC, Cheng XS, Woodside KJ, Parajuli S, Lentine KL, **Kaplan B**, Segev DL, Kobashigawa JA, Dadhania D, AST Kidney Pancreas Community of Practice Workgroup. Perceptions and Practices Regarding Frailty in Kidney Transplantation: Results of a National Survey. *Transplantation*. 2020 Feb;104(2):349-356. doi: 10.1097/TP.0000000000002779.
319. Naesens M, Friedewald J, Mas V, **Kaplan B**, Abecassis MM. A Practical guide to the clinical Implementation of Biomarkers for Subclinical Rejection Following Kidney Transplantation. *Transplantation*. 2020 Apr;104(4):700-707. doi:10.1097/TP.0000000000003064.
320. Sapir-Pichhadze R, **Kaplan B**. Seeing the Forest for the Trees: Random Forest Models for predicting Survival in Kidney Transplant Recipients. *Transplantation*. 2020 May;104(5):905-906. doi: 10.1097/TP.0000000000002923.
321. Harhay NM, Rao MK, Woodside KL, Johansen KL< Lentine KL, Tullius SG, Parsons RF, Almamad T, Berger J, Cheng XS, Lappin J, Lynch R, Parajuli S, Tan JC, Segev DL, **Kaplan B**, Kobashigawa J, Dadhania DM, McAdams-DeMarco MA. An overview if frailty in kidney transplantation: measurement, management, and future considerations. *Nephrol Dial Transplant*. 2020 Jul 1;35(7):1099-1112. doi: 10.1093/ndt/gfaa016.
322. Fleishman A, Khwaja K, Schold JD, Comer CD, Morrissey P, Whiting J, Vella J, Jaler LK, Katz D, Jones J, **Kaplan B**, Pavlakis M, Mandelbrot DA, Rodriguez JR, KDOC study group. Pain expectancy, prevalence, severity and patterns following donor nephrectomy: Findings from the KDOC Study. *Am J Transplant*. 2020 Sep;20(9):2522-2529. doi: 10.1111/ajt.15861
323. Budhiraja P, Kalot M, Alayli AE, Dimassi A, **Kaplan B**, Chakkera HA, Mustafa RA. Reporting and handling of missing participant data in systematic reviews of kidney transplant studies. *Transplantation*. 2020 Oct 21. doi: 10.1097/TP.0000000000003503.
324. Bromberg J, Baan C, Chapman J, Anegon I, Brennan DC, Chakera A, Chong AS, Geissler EK, Guillonneau C, Heaton N, Hesselink DA, Jassem W, Jones CM, Josien R, **Kaplan B**, Kaufman CL, Lim W, Ma Y, Massey E,

- Ostrander DB, Slaughter MS, Tullis S, Witkowski P, Wong G. The Impact of COVID-19 on the State of Clinical and Laboratory Research Globally in Transplantation in May 2020. *Transplantation*. 2020 Nov;104(11):2252-2257. doi: 10.1097/TP.0000000000003362.
325. Dutcher EG, Green EP, **Kaplan B**. Using Behavioral Economics to Increase Transplantation Through Commitments to Donate. *Transplantation*. 2020 Dec;104(121):2467-2468. doi: 10.1097/TP.0000000000003182.
 326. Park SH, Mazumder NR, Mehrotra S, Ho B, **Kaplan B**, Ladner DR. Artificial Intelligence-related Literature in Transplantation: A Practical Guide. *Transplantation*. 2021 Apr 1;105(4):704-704. doi: 10.1097/TP.0000000000003304.
 327. Edwards AS, **Kaplan B**, Jie T. A Primer on Machine Learning. *Transplantation*. 2021 Apr 1;105(4):699-703. doi: 10.1097/TP.0000000000003316.
 328. Budhiraja P, **Kaplan B**, Kalot M, Alayi AE, Dimassi A, Chakkera HA, Heilman R, Edwards AS, Mustafa RA. Current State of Evidence on Kidney Transplantation: How Fragile Are the Results? *Transplantation*, 2021 May 6. doi: 10.1097/TP.0000000000003805.
 329. Singh N, Friedewald J, Bloom R, Dadhania D, Parsons RF, **Kaplan B**, Samaniego M, Qazi Y, Doshi M, McNatt G, Naseer MS, Pesavento T, Wiseman A. Transplant administration- A survey of the roles and responsibilities of kidney and pancreas medical directors of US transplant centers. *Clin Transplant*. 2021 Jun;35(6):e14305. doi: 10.1111/ctr.14305
 330. Kastelz A, Fernhall B, Wang E, Tzvetanov I, Spaggiari M, Shetty A, Gallon L, Hachaj G, **Kaplan B**, Benedetti E. Personalized physical rehabilitation program and employment in kidney transplant recipients: a randomized trial. *Transpl Int*. 2021 Jun;34(6):1083-1092. doi: 10.1111/tri.13868.
 331. West-Thielke PM, Ipema HJ, Campbell-Lee S, Benedetti E, **Kaplan B**, Thielke JJ. Removal of Anti-Thymocyte Globulin by Plasma Exchange in ABO-Incompatible and Positive Crossmatch Kidney Transplant Recipients. *Transplant Proc*. 2021 Jun;53(5):1548-1553. doi: 10.1016/j.transproceed.2021.01.010.
 332. Akanit U, Bozorgmehri S, Alquadan K, Nelson J, **Kaplan B**, Ozrazgat-Baslanti T, Womer KL. Improved ability to achieve target trough levels with liquid versus capsule tacrolimus in kidney transplant patients with HIV on protease inhibitor or cobicistat-based regimens. *Transpl Infect Dis*. 2021 Jun;23(3):e13517. doi: 10.1111/tid.13517.